Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Varsha Gandhi, PhD, on Ibrutinib

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Apr
05
Today In Oncology
Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin
FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL
AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation
Prompting Strategies Improve Symptom Monitoring in Childhood Cancer Survivors
Patients With Lung Cancer May Safely Receive Adequate SBRT Dosage in One Treatment
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo